Loading patent…
AssigneesTokushima University, Oncotherapy Science, Inc.
InventorsToyomasa Katagiri, Tetsuro Yoshimaru, Akira Otaka, Takashi Miyamoto, Yasuhide Okamoto
Estimating the term…
The present invention provides peptides containing the BIG3 polypeptide-binding site in a PHB2 polypeptide, which inhibit the binding between a PHB2 polypeptide and a BIG3 polypeptide, and pharmaceutical compositions containing the peptide. The peptides of the present invention have the ability to bind not to PHB2, whose expression is found in organs throughout the human body, but to BIG3, which is a protein highly expressed specifically in particularly estrogen receptor-positive cancer, and have excellent growth suppressive effects on BIG3-positive cancer cells. Accordingly, the peptides of the present invention are useful as therapeutic agents for breast cancer which can avoid expression of side effects.
A cyclic peptide, comprising a site binding to a BIG3 polypeptide in a PHB2 polypeptide, wherein the cyclic peptide inhibits the binding between the PHB2 polypeptide and the BIG3 polypeptide, wherein the cyclic peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NOs:
Dependencies are inferred from the claim text.